Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 4Carcinoma, Non-Small-Cell Lung 3Lung Neoplasms 2Leukemia, Myeloid, Acute 2Carcinoma, Renal Cell 2Brain Neoplasms 2Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Rectal Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neuroendocrine Tumors (pNET) 1Oropharyngeal Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms 1Melanoma 1Lymphoma, Mantle-Cell 1Head and Neck Neoplasms 1Carcinoma, Squamous Cell 1Breast Neoplasms 1Breast Carcinoma In Situ 1Anus Neoplasms 1Anatomic Stage II Breast Cancer AJCC v8 1Anal Canal Carcinoma 1

Interventions

Gemcitabine 6Mitomycin 4erdafitinib 3viscum album peptide 1pirarubicin 1hydroxycamptothecinum 1durvalumab 1Watchful Waiting 1Transurethral Resection of Bladder 1Magnetic Resonance Spectroscopy 1Injections 1Epirubicin 1Cystoscopy 1BCG Vaccine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Non-Muscle Invasive Bladder Neoplasms × Watchful Waiting × 30 days × Clear all
NCT07625527 2026-06-04

Is Prolonged Systemic Immunotherapy Necessary After Achieving Tumor-free Status in Patients With Extensive Transurethrally Unresectable Very-high-risk NMIBC?

Tianjin Medical University Second Hospital

Phase 2 Not yet recruiting
120 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡